Pfizer: AIDS-Related Complex trials

The registry lists 11 AIDS-Related Complex studies with Pfizer as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 1Phase 3 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are CommonCompletedNCT00002325Not applicable
• A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive PatientsCompletedNCT00002322Phase 2
• A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected PatientsCompletedNCT00002309Not applicable
• An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC PatientsCompletedNCT00002266Not applicable
• A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3CompletedNCT00002124Phase 3
• A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3CompletedNCT00002123Phase 3
• Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency SyndromeCompletedNCT00002112Not applicable
• Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected IndividualsCompletedNCT00002087Phase 1
• Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND StudyCompletedNCT00002080Not applicable
• A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced DiseaseCompletedNCT00002033Not applicable
• A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC PatientsCompletedNCT00002013Not applicable